Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Actelion |
---|---|
Information provided by: | Actelion |
ClinicalTrials.gov Identifier: | NCT00453414 |
The purpose of this study is to evaluate the safety and effectiveness of iloprost for PAH in children who are between the ages of 3 and 18 years old.
Condition | Intervention | Phase |
---|---|---|
Pulmonary Arterial Hypertension |
Drug: Iloprost Inhalation Solution (Ventavis) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension |
Estimated Enrollment: | 24 |
Study Start Date: | July 2006 |
Ages Eligible for Study: | 3 Years to 18 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Colorado | |
The Children's Hospital | |
Denver, Colorado, United States, 80218 | |
United States, New York | |
Columbia University Medical Center | |
New York, New York, United States, 10032 |
Study ID Numbers: | C200-007 |
Study First Received: | March 27, 2007 |
Last Updated: | June 13, 2007 |
ClinicalTrials.gov Identifier: | NCT00453414 History of Changes |
Health Authority: | United States: Food and Drug Administration |
PAH Pediatric Pulmonary Arterial Hypertension |
Iloprost Vasodilator Agents Respiratory Tract Diseases Hypertension, Pulmonary Lung Diseases |
Idiopathic Pulmonary Hypertension Vascular Diseases Platelet Aggregation Inhibitors Cardiovascular Agents Hypertension |
Vasodilator Agents Hematologic Agents Vascular Diseases Cardiovascular Agents Pharmacologic Actions Iloprost Respiratory Tract Diseases |
Hypertension, Pulmonary Lung Diseases Therapeutic Uses Cardiovascular Diseases Platelet Aggregation Inhibitors Hypertension |